SOUTH SAN FRANCISCO, Calif. , Aug. 06, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that the Compensation Committee of its Board of Directors, which is comprised entirely of independent directors, granted equity awards effective as of July 31, 2018 , under Fluidigm's
Total revenue increases 11 percent to $26.4 million Mass cytometry revenue growth of 32 percent Total consumables revenue growth of 19 percent SOUTH SAN FRANCISCO, Calif. , Aug. 02, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced financial results for the second quarter
Providing more affordable full-length single-cell mRNA sequencing with industry-leading coverage and sensitivity for in-depth cellular characterization SOUTH SAN FRANCISCO, Calif. , July 31, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation , a leader in mass cytometry and microfluidics technologies,
Pairing epigenetic profiling with T cell receptor sequencing at single-cell resolution to advance cancer, immunology and stem cell research SOUTH SAN FRANCISCO, Calif. , July 10, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation , a leader in mass cytometry and microfluidics technologies, today
SOUTH SAN FRANCISCO, Calif. , July 05, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative life science company that develops, manufactures and markets multiparameter mass cytometry and proprietary microfluidics systems used in research and applied markets, announced today
SOUTH SAN FRANCISCO, Calif. , June 26, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the appointment of David King as Vice President, Research and Development, Genomics. As a member of the executive leadership team reporting to President and CEO Chris Linthwaite , King
Joint offering enables acceleration of genomic panel design for translational and clinical disease research SOUTH SAN FRANCISCO, Calif. , June 07, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation announced today that it has entered into a co-marketing agreement with Genomenon to offer evidence-based
Standardizing human sample identification using automated genomic microfluidic systems that reduce hands-on time and cost per sample SOUTH SAN FRANCISCO, Calif. , June 05, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the introduction of the Advanta™ Sample ID
SOUTH SAN FRANCISCO, Calif. , May 10, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that the Compensation Committee of its Board of Directors, which is comprised entirely of independent directors, granted equity awards effective as of May 8, 2018 , under Fluidigm's
SOUTH SAN FRANCISCO, Calif. , May 09, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative life science company that develops, manufactures and markets multiparameter mass cytometry technology and proprietary microfluidics systems used in research and applied markets,